A message to the Fragile X community from Dr. Dayno on behalf of the team at Harmony Biosciences:
Representatives from Harmony Biosciences will be attending the 19th International Fragile X Conference with us in Orlando, Florida. They are excited to come together with the Fragile X community to listen, learn, and help pave the way for brighter futures.
If you see a member of the Harmony Biosciences team, don’t hesitate to say “hello” and ask about about their commitment to the Fragile X community and advancing science and treatment options.
learn more
Visit the RECONNECT MyFXReserach post for more infromation:
Clinical Trial RECONNECT: ZYN002 Gel | MyFXResearch Portal (fragilex.org)
Allos Pharma Inc. Receives FDA Guidance and Support for their Phase 3 Trial of Arbaclofen in Fragile X Syndrome
Allos Pharma Inc. received invaluable FDA feedback on the design of their Phase 3 trial for arbaclofen for the treatment of Fragile X syndrome.
Survey: Developing a Caregiver-Reported Survey in Neurodevelopmental Disorders: The Neurodevelopmental Disorder-Health Index (NDD-HI)
The Center of Health and Technology’s (CheT) Outcomes Division is conducting is conducting a survey to learn about the most prevalent and impactful symptoms of FXS that the individual experiences, as reported by the caregiver.